Alfasigma (Italy)

Recent papers from Alfasigma (Italy)

1. Detecting Chestnut Ink Diseases Through the Dog's Sense of Smell: From Laboratory to ForestPlant Pathology · 2026
2. Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH StudiesRheumatology and Therapy · 2026
3. Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studiesAnnals of the Rheumatic Diseases · 2026
4. Personalized Radionuclide Therapy via Avidin-Biotin Pretargeting: Biodistribution and Dosimetry of ¹⁷⁷ Lu-DOTA-biotin with AvidinOX™ in Solid TumorsCancer Biotherapy and Radiopharmaceuticals · 2026
5. An Open Pharma Vision for company-sponsored biomedical research publicationsBMJ Open · 2026
6. E093 Overall safety profile and laboratory parameters in patients with rheumatoid arthritis treated with filgotinib for up to 2 years: real-world evidence from FILOSOPHY and PARROTFISHLara D. Veeken · 2026
7. E102 Characterisation of patients with rheumatoid arthritis based on distinct patterns of pain improvement following treatment with filgotinib: a post hoc analysis of FINCH 1Lara D. Veeken · 2026
8. E094 Early and sustained improvements in disease activity and patient-reported outcomes in patients treated with filgotinib for rheumatoid arthritis: up to 2-year interim real-world data from FILOSOPHY and PARROTFISHLara D. Veeken · 2026
9. Rifaximin Ameliorates Urea Cycle Disorder in a Murine Model of humanOrnithine Transcarbamylase DeficiencyThe International Journal of Gastroenterology and Hepatology Diseases · 2026
10. Integrated Safety Analysis of Filgotinib in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis Over a Treatment Duration of up to 5 YearsModern Rheumatology · 2026
11. Cold Atmospheric Plasma Applications in Viral Inactivation: Systematic Review and MetanalysisPlasma Chemistry and Plasma Processing · 2026
12. Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinib.2026
13. DOP036Real-world corticosteroid use in patients with Ulcerative Colitis receiving filgotinib up to week 24: An interim analysis from the prospective, observational GALOCEAN studyJournal of Crohn s and Colitis · 2026
14. P1068Real-world effectiveness of filgotinib by prior advanced treatment and predictors of clinical response in Ulcerative Colitis: Interim results up to week 24 from the prospective, observational GALOCEAN studyJournal of Crohn s and Colitis · 2026
15. Clinical Trial: Efficacy and Safety of Velusetrag in Chronic Intestinal Pseudo‐Obstruction: A Randomized, Phase 2, Placebo‐Controlled, Crossover, Multiple ( n  = 1), Proof‐of‐Concept StudyNeurogastroenterology & Motility · 2026
16. Rheumatologist and patient perspectives on axial spondyloarthritis management and treatment satisfaction in EuropeSeminars in Arthritis and Rheumatism · 2025
17. Survival and Impact on Microbial Diversity of Lacticaseibacillus paracasei DG in a Simulation of Human Intestinal Microbial EcosystemNutrients · 2025
18. Fluoromethylcarnitine, a novel inhibitor of trimethylamine levels in trimethylaminuria and trimethylamine N-oxide related disordersEuropean Journal of Medicinal Chemistry · 2025
19. Genetic and phenotypic stability of Lacticaseibacillus paracasei DG (DSM 34154) over 10 years of industrial productionApplied and Environmental Microbiology · 2025
20. Filgotinib Radiographic and Clinical Efficacy Versus Other JAK Inhibitors and Adalimumab in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Systematic Review and Network Meta-AnalysisRheumatology and Therapy · 2025